Avaliação da função renal no pós-operatório de pacientes submetidos a revascularização do miocárdio com uso de dexmedetomidina
Carregando...
Data
2013-02-25
Autores
Martucci, Alexandre Fabrício [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O aumento sérico da creatinina em 0,3mg/dL define o termo lesão renal aguda (LRA) e associa-se a maior incidência de mortalidade pós-operatória em pacientes submetidos a revascularização do miocárdio. Os estudos clínicos quanto à influência da dexmedetomidina (DEX) sobre a função renal ainda são escassos. Avaliou-se a LRA no pós operatório de revascularização do miocárdio com e sem circulação extracorpórea (CEC) quando se anestesiou com DEX. Neste estudo, retrospectivo, fez-se análise seriada da creatinina sérica (CrS) até 48h de pós-operatório de 286 pacientes submetidos a revascularização do miocárdio para avaliar a incidência de LRA. Testou-se a homogeneidade entre os grupos, avaliando-se os pacientes separadamente quanto ao uso de CEC e de DEX. Cada paciente foi avaliado em relação à sua concentração sanguínea de creatinina nos períodos pré-operatório, pós-operatório imediato, de 24h e de 48h. Em cada período foi efetuada a comparação da concentração de creatinina com a concentração no pré-operatório. Se em pelo menos um dos períodos esta comparação indicou aumento de creatinina≥0,3 mg/dL, o paciente foi classificado como tendo LRA. Foi também avaliado o risco de LRA em pacientes com creatinina sanguínea pré-operatória alterada (valores entre 1,1 a 2,0mg/dL para mulheres ou 1,3 a 2,0mg/dL para homens) em comparação com os pacientes com creatinina normal.Os resultados foram homogêneos quanto a peso, idade e creatinina alterada no pré-operatório e os pacientes que fizeram uso de DEX e foram submetidos a CEC apresentaram maior incidência de LRA, com p=0,043. Dentre aqueles que não foram submetidos a CEC, houve maior incidência de LRA após DEX, porém com p=0,066.O uso da DEX no intraoperatório aumentou a incidência de LRA no pós-operatório de revascularização do miocárdio de pacientes submetidos a CEC
The increase of 0.3mg/dL in serum creatinine defines the term acute kidney injury (AKI) and is associated with higher incidence of postoperative mortality in patients undergoing coronary artery bypass grafting surgery (CABG). Clinical studies regarding the influence of dexmedetomidine (DEX) on renal function are scarce. We evaluated the LRA in postoperative of patients submitted to CABG with and without cardiopulmonary bypass (CPB) under anesthesia with DEX. In this retrospective study it was made serial analysis of serum creatinine (SCr) until 48h after the surgery of 286 patients undergoing CABG under DEX to evaluate the incidence of AKI. We tested the homogeneity among groups, evaluating patients separately for the use of CPB and DEX. Each patient was evaluated with respect to their blood concentration of creatinine in the preoperative and postoperative: early, 24h and 48h. In each period, it was compared the creatinine concentration with creatinine concentration preoperatively. If at least in one of the periods this comparison showed increased creatinine ≥ 0.3mg/dL, the patient was classified as having AKI. It has also assessed the risk of AKI in patients with preoperative blood creatinine changed: values between 1.1 to 2.0mg/dL for females or 1.3 to 2.0mg/dL for men compared with patients with normal creatinine concentration. The results were homogeneous for weight, age and creatinine concentration altered to 2.0mg/dL preoperatively. Patients who used DEX and underwent CPB had a higher incidence of AKI, with p = 0.043. Among those who were not undergoing CPB, there was a higher incidence of AKI after DEX, but with p = 0.066. Conclusion. The use of intraoperative DEX increased the incidence of AKI in the postoperative myocardial revascularization in patients undergoing CPB
The increase of 0.3mg/dL in serum creatinine defines the term acute kidney injury (AKI) and is associated with higher incidence of postoperative mortality in patients undergoing coronary artery bypass grafting surgery (CABG). Clinical studies regarding the influence of dexmedetomidine (DEX) on renal function are scarce. We evaluated the LRA in postoperative of patients submitted to CABG with and without cardiopulmonary bypass (CPB) under anesthesia with DEX. In this retrospective study it was made serial analysis of serum creatinine (SCr) until 48h after the surgery of 286 patients undergoing CABG under DEX to evaluate the incidence of AKI. We tested the homogeneity among groups, evaluating patients separately for the use of CPB and DEX. Each patient was evaluated with respect to their blood concentration of creatinine in the preoperative and postoperative: early, 24h and 48h. In each period, it was compared the creatinine concentration with creatinine concentration preoperatively. If at least in one of the periods this comparison showed increased creatinine ≥ 0.3mg/dL, the patient was classified as having AKI. It has also assessed the risk of AKI in patients with preoperative blood creatinine changed: values between 1.1 to 2.0mg/dL for females or 1.3 to 2.0mg/dL for men compared with patients with normal creatinine concentration. The results were homogeneous for weight, age and creatinine concentration altered to 2.0mg/dL preoperatively. Patients who used DEX and underwent CPB had a higher incidence of AKI, with p = 0.043. Among those who were not undergoing CPB, there was a higher incidence of AKI after DEX, but with p = 0.066. Conclusion. The use of intraoperative DEX increased the incidence of AKI in the postoperative myocardial revascularization in patients undergoing CPB
Descrição
Palavras-chave
Rins - Doenças, Coração - Cirurgia, Miocardio - Doenças, Anestesicos - Efeito fisiologico, Kidneys - Diseases
Como citar
MARTUCCI, Alexandre Fabrício. Avaliação da função renal no pós-operatório de pacientes submetidos a revascularização do miocárdio com uso de dexmedetomidina. 2013. 54 f. Dissertação (mestrado) - Universidade Estadual Paulista Julio de Mesquita Filho, Faculdade de Medicina de Botucatu, 2013.